BioSyntech, Inc. Stock Other OTC

BSYI

CA09068L1031

Biotechnology & Medical Research

OTC Markets Traded

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNTECH, INC.	-.--%	-.--%	-	-	1.16K
LONZA GROUP AG	+0.63%	+2.53%	+6.13%	+15.32%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+592.61%	43.97B
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+73.63%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.15%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+47.53%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+122.50%	16.49B
EUROFINS SCIENTIFIC SE	-0.26%	+2.78%	+5.07%	+18.08%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+23.95%	12.77B
Average	+1.85%	+6.32%	+85.87%	+112.85%	29.43B
Weighted average by Cap.	+2.46%	+6.10%	+105.35%	+137.93%

See all sector performances

BioSyntech, Inc. is a Canada-based biotechnology company. The Company is developing biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The Company's platform technology is a family of hydrogels called BST-Gel, some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offers properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The Company's lead, late-stage product, BST-CarGel is undergoing an international pivotal trial.

Employees

Sector

Biotechnology & Medical Research

More about the company